Better data, lower prices and an important precedent for restricting access to drugs given accelerated approval by the FDA
Three takeaways from the CMS Aduhelm decision
Three takeaways from the CMS Aduhelm decision
Three takeaways from the CMS Aduhelm decision
Better data, lower prices and an important precedent for restricting access to drugs given accelerated approval by the FDA